Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

3.15
-0.1100-3.37%
Post-market: 3.190.0400+1.27%19:44 EDT
Volume:1.28M
Turnover:4.04M
Market Cap:263.70M
PE:-1.04
High:3.28
Open:3.28
Low:3.10
Close:3.26
Loading ...

Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position

TIPRANKS
·
07 Mar

Editas Medicine Inc.’s Stock Volatility: Key Risks and Investor Considerations

TIPRANKS
·
07 Mar

Analysts’ Top Healthcare Picks: Editas Medicine (EDIT), Viking Therapeutics (VKTX)

TIPRANKS
·
07 Mar

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

Zacks
·
06 Mar

Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)

TIPRANKS
·
06 Mar

Editas Medicine: Balancing Financial Stability and Strategic Uncertainties with a Hold Rating

TIPRANKS
·
06 Mar

Editas Medicine Reports Progress in Gene Editing

TIPRANKS
·
06 Mar

Editas Medicine Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
06 Mar

Editas: Q4 Earnings Snapshot

Associated Press Finance
·
06 Mar

Editas Medicine Q4 2024 GAAP EPS $(0.55) Misses $(0.38) Estimate, Sales $30.604M Miss $32.230M Estimate

Benzinga
·
06 Mar

BRIEF-Editas Medicine Q4 Net Income USD -45.395 Million

Reuters
·
06 Mar

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

GlobeNewswire
·
06 Mar

Editas Medicine Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
03 Mar

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

GlobeNewswire
·
24 Feb

Editas Medicine Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
24 Feb